Pharma & Healthcare

Global Anti-VEGF Therapy for Cancer Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Anti-VEGF Therapy for Cancer market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Sanofi
Eli Lilly
Roche
Bayer
Pfizer
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
AstraZeneca
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Segment by Type
VEGF Inhibitors
VEGFR Inhibitors
Segment by Application
Colorectal Cancer
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Cervical Cancer
Medullary Thyroid Cancer
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Anti-VEGF Therapy for Cancer study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Anti-VEGF Therapy for Cancer: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 VEGF Inhibitors
1.2.3 VEGFR Inhibitors
1.3 Market Segmentation by Application
1.3.1 Global Anti-VEGF Therapy for Cancer Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Colorectal Cancer
1.3.3 Non-small Cell Lung Cancer
1.3.4 Renal Cell Carcinoma
1.3.5 Cervical Cancer
1.3.6 Medullary Thyroid Cancer
1.3.7 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-VEGF Therapy for Cancer Revenue Estimates and Forecasts 2020-2031
2.2 Global Anti-VEGF Therapy for Cancer Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Anti-VEGF Therapy for Cancer Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Anti-VEGF Therapy for Cancer Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 VEGF Inhibitors Market Size by Players
3.3.2 VEGFR Inhibitors Market Size by Players
3.4 Global Anti-VEGF Therapy for Cancer Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Anti-VEGF Therapy for Cancer Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Anti-VEGF Therapy for Cancer Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Anti-VEGF Therapy for Cancer Market Size by Type (2020-2031)
6.4 North America Anti-VEGF Therapy for Cancer Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Anti-VEGF Therapy for Cancer Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Anti-VEGF Therapy for Cancer Market Size by Type (2020-2031)
7.4 Europe Anti-VEGF Therapy for Cancer Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Anti-VEGF Therapy for Cancer Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Type (2020-2031)
8.4 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Anti-VEGF Therapy for Cancer Market Size by Type (2020-2031)
9.4 Central and South America Anti-VEGF Therapy for Cancer Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Anti-VEGF Therapy for Cancer Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Anti-VEGF Therapy for Cancer Market Size by Type (2020-2031)
10.4 Middle East and Africa Anti-VEGF Therapy for Cancer Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Anti-VEGF Therapy for Cancer Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Anti-VEGF Therapy for Cancer Product Features and Attributes
11.1.4 Sanofi Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.1.5 Sanofi Anti-VEGF Therapy for Cancer Revenue by Product in 2024
11.1.6 Sanofi Anti-VEGF Therapy for Cancer Revenue by Application in 2024
11.1.7 Sanofi Anti-VEGF Therapy for Cancer Revenue by Geographic Area in 2024
11.1.8 Sanofi Anti-VEGF Therapy for Cancer SWOT Analysis
11.1.9 Sanofi Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Anti-VEGF Therapy for Cancer Product Features and Attributes
11.2.4 Eli Lilly Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly Anti-VEGF Therapy for Cancer Revenue by Product in 2024
11.2.6 Eli Lilly Anti-VEGF Therapy for Cancer Revenue by Application in 2024
11.2.7 Eli Lilly Anti-VEGF Therapy for Cancer Revenue by Geographic Area in 2024
11.2.8 Eli Lilly Anti-VEGF Therapy for Cancer SWOT Analysis
11.2.9 Eli Lilly Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche Anti-VEGF Therapy for Cancer Product Features and Attributes
11.3.4 Roche Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.3.5 Roche Anti-VEGF Therapy for Cancer Revenue by Product in 2024
11.3.6 Roche Anti-VEGF Therapy for Cancer Revenue by Application in 2024
11.3.7 Roche Anti-VEGF Therapy for Cancer Revenue by Geographic Area in 2024
11.3.8 Roche Anti-VEGF Therapy for Cancer SWOT Analysis
11.3.9 Roche Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview
11.4.3 Bayer Anti-VEGF Therapy for Cancer Product Features and Attributes
11.4.4 Bayer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.4.5 Bayer Anti-VEGF Therapy for Cancer Revenue by Product in 2024
11.4.6 Bayer Anti-VEGF Therapy for Cancer Revenue by Application in 2024
11.4.7 Bayer Anti-VEGF Therapy for Cancer Revenue by Geographic Area in 2024
11.4.8 Bayer Anti-VEGF Therapy for Cancer SWOT Analysis
11.4.9 Bayer Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Anti-VEGF Therapy for Cancer Product Features and Attributes
11.5.4 Pfizer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Anti-VEGF Therapy for Cancer Revenue by Product in 2024
11.5.6 Pfizer Anti-VEGF Therapy for Cancer Revenue by Application in 2024
11.5.7 Pfizer Anti-VEGF Therapy for Cancer Revenue by Geographic Area in 2024
11.5.8 Pfizer Anti-VEGF Therapy for Cancer SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.6.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Features and Attributes
11.6.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Corporation Information
11.7.2 Chia Tai Tianqing Business Overview
11.7.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Features and Attributes
11.7.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.7.5 Chia Tai Tianqing Recent Developments
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Business Overview
11.8.3 Novartis Anti-VEGF Therapy for Cancer Product Features and Attributes
11.8.4 Novartis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.8.5 Novartis Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Corporation Information
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Anti-VEGF Therapy for Cancer Product Features and Attributes
11.9.4 AstraZeneca Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.9.5 AstraZeneca Recent Developments
11.10 Exelixis
11.10.1 Exelixis Corporation Information
11.10.2 Exelixis Business Overview
11.10.3 Exelixis Anti-VEGF Therapy for Cancer Product Features and Attributes
11.10.4 Exelixis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Corporation Information
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Features and Attributes
11.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.11.5 Boehringer Ingelheim Recent Developments
11.12 Eisai
11.12.1 Eisai Corporation Information
11.12.2 Eisai Business Overview
11.12.3 Eisai Anti-VEGF Therapy for Cancer Product Features and Attributes
11.12.4 Eisai Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.12.5 Eisai Recent Developments
11.13 Janssen Biotech
11.13.1 Janssen Biotech Corporation Information
11.13.2 Janssen Biotech Business Overview
11.13.3 Janssen Biotech Anti-VEGF Therapy for Cancer Product Features and Attributes
11.13.4 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2020-2025)
11.13.5 Janssen Biotech Recent Developments
12 Anti-VEGF Therapy for CancerIndustry Chain Analysis
12.1 Anti-VEGF Therapy for Cancer Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Anti-VEGF Therapy for Cancer Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Anti-VEGF Therapy for Cancer Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-VEGF Therapy for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-VEGF Therapy for Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-VEGF Therapy for Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Anti-VEGF Therapy for Cancer Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Anti-VEGF Therapy for Cancer by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapy for Cancer as of 2024)
Table 11. Global Anti-VEGF Therapy for Cancer Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Anti-VEGF Therapy for Cancer Companies Headquarters
Table 13. Global Anti-VEGF Therapy for Cancer Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Anti-VEGF Therapy for Cancer Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Anti-VEGF Therapy for Cancer Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Anti-VEGF Therapy for Cancer Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Anti-VEGF Therapy for Cancer Revenue by Application (2026-2031) & (US$ Million)
Table 21. Anti-VEGF Therapy for Cancer High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Anti-VEGF Therapy for Cancer Growth Accelerators and Market Barriers
Table 25. North America Anti-VEGF Therapy for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Anti-VEGF Therapy for Cancer Growth Accelerators and Market Barriers
Table 27. Europe Anti-VEGF Therapy for Cancer Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Anti-VEGF Therapy for Cancer Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Anti-VEGF Therapy for Cancer Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Anti-VEGF Therapy for Cancer Investment Opportunities and Key Challenges
Table 31. Central and South America Anti-VEGF Therapy for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Anti-VEGF Therapy for Cancer Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Anti-VEGF Therapy for Cancer Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Sanofi Corporation Information
Table 35. Sanofi Description and Major Businesses
Table 36. Sanofi Product Features and Attributes
Table 37. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Sanofi Revenue Proportion by Product in 2024
Table 39. Sanofi Revenue Proportion by Application in 2024
Table 40. Sanofi Revenue Proportion by Geographic Area in 2024
Table 41. Sanofi Anti-VEGF Therapy for Cancer SWOT Analysis
Table 42. Sanofi Recent Developments
Table 43. Eli Lilly Corporation Information
Table 44. Eli Lilly Description and Major Businesses
Table 45. Eli Lilly Product Features and Attributes
Table 46. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Eli Lilly Revenue Proportion by Product in 2024
Table 48. Eli Lilly Revenue Proportion by Application in 2024
Table 49. Eli Lilly Revenue Proportion by Geographic Area in 2024
Table 50. Eli Lilly Anti-VEGF Therapy for Cancer SWOT Analysis
Table 51. Eli Lilly Recent Developments
Table 52. Roche Corporation Information
Table 53. Roche Description and Major Businesses
Table 54. Roche Product Features and Attributes
Table 55. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Roche Revenue Proportion by Product in 2024
Table 57. Roche Revenue Proportion by Application in 2024
Table 58. Roche Revenue Proportion by Geographic Area in 2024
Table 59. Roche Anti-VEGF Therapy for Cancer SWOT Analysis
Table 60. Roche Recent Developments
Table 61. Bayer Corporation Information
Table 62. Bayer Description and Major Businesses
Table 63. Bayer Product Features and Attributes
Table 64. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Bayer Revenue Proportion by Product in 2024
Table 66. Bayer Revenue Proportion by Application in 2024
Table 67. Bayer Revenue Proportion by Geographic Area in 2024
Table 68. Bayer Anti-VEGF Therapy for Cancer SWOT Analysis
Table 69. Bayer Recent Developments
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Major Businesses
Table 72. Pfizer Product Features and Attributes
Table 73. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Pfizer Revenue Proportion by Product in 2024
Table 75. Pfizer Revenue Proportion by Application in 2024
Table 76. Pfizer Revenue Proportion by Geographic Area in 2024
Table 77. Pfizer Anti-VEGF Therapy for Cancer SWOT Analysis
Table 78. Pfizer Recent Developments
Table 79. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 80. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 81. Jiangsu Hengrui Pharmaceuticals Product Features and Attributes
Table 82. Jiangsu Hengrui Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 84. Chia Tai Tianqing Corporation Information
Table 85. Chia Tai Tianqing Description and Major Businesses
Table 86. Chia Tai Tianqing Product Features and Attributes
Table 87. Chia Tai Tianqing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Chia Tai Tianqing Recent Developments
Table 89. Novartis Corporation Information
Table 90. Novartis Description and Major Businesses
Table 91. Novartis Product Features and Attributes
Table 92. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Novartis Recent Developments
Table 94. AstraZeneca Corporation Information
Table 95. AstraZeneca Description and Major Businesses
Table 96. AstraZeneca Product Features and Attributes
Table 97. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. AstraZeneca Recent Developments
Table 99. Exelixis Corporation Information
Table 100. Exelixis Description and Major Businesses
Table 101. Exelixis Product Features and Attributes
Table 102. Exelixis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Exelixis Recent Developments
Table 104. Boehringer Ingelheim Corporation Information
Table 105. Boehringer Ingelheim Description and Major Businesses
Table 106. Boehringer Ingelheim Product Features and Attributes
Table 107. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Boehringer Ingelheim Recent Developments
Table 109. Eisai Corporation Information
Table 110. Eisai Description and Major Businesses
Table 111. Eisai Product Features and Attributes
Table 112. Eisai Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Eisai Recent Developments
Table 114. Janssen Biotech Corporation Information
Table 115. Janssen Biotech Description and Major Businesses
Table 116. Janssen Biotech Product Features and Attributes
Table 117. Janssen Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Janssen Biotech Recent Developments
Table 119. Raw Materials Key Suppliers
Table 120. Distributors List
Table 121. Market Trends and Market Evolution
Table 122. Market Drivers and Opportunities
Table 123. Market Challenges, Risks, and Restraints
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources


List of Figures
Figure 1. Anti-VEGF Therapy for Cancer Product Picture
Figure 2. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. VEGF Inhibitors Product Picture
Figure 4. VEGFR Inhibitors Product Picture
Figure 5. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Colorectal Cancer
Figure 7. Non-small Cell Lung Cancer
Figure 8. Renal Cell Carcinoma
Figure 9. Cervical Cancer
Figure 10. Medullary Thyroid Cancer
Figure 11. Other
Figure 12. Anti-VEGF Therapy for Cancer Report Years Considered
Figure 13. Global Anti-VEGF Therapy for Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 15. Global Anti-VEGF Therapy for Cancer Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Region (2020-2031)
Figure 17. Global Anti-VEGF Therapy for Cancer Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. VEGF Inhibitors Revenue Market Share by Player in 2024
Figure 20. VEGFR Inhibitors Revenue Market Share by Player in 2024
Figure 21. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2020-2031)
Figure 22. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2020-2031)
Figure 23. North America Anti-VEGF Therapy for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Anti-VEGF Therapy for Cancer Revenue (US$ Million) in 2024
Figure 25. North America Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Anti-VEGF Therapy for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Anti-VEGF Therapy for Cancer Revenue (US$ Million) in 2024
Figure 32. Europe Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 35. France Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Anti-VEGF Therapy for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Anti-VEGF Therapy for Cancer Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 47. India Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Anti-VEGF Therapy for Cancer Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Anti-VEGF Therapy for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Anti-VEGF Therapy for Cancer Revenue (US$ Million) in 2024
Figure 55. Central and South America Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Anti-VEGF Therapy for Cancer Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Anti-VEGF Therapy for Cancer Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Anti-VEGF Therapy for Cancer Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Anti-VEGF Therapy for Cancer Revenue (US$ Million) in 2024
Figure 61. South America Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Anti-VEGF Therapy for Cancer Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Anti-VEGF Therapy for Cancer Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Anti-VEGF Therapy for Cancer Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Anti-VEGF Therapy for Cancer Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Anti-VEGF Therapy for Cancer Revenue (2020-2025) & (US$ Million)
Figure 67. Anti-VEGF Therapy for Cancer Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies